GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RenovaCare Inc (OTCPK:RCAR) » Definitions » Forward PE Ratio

RenovaCare (RenovaCare) Forward PE Ratio : 0.00 (As of May. 12, 2024)


View and export this data going back to . Start your Free Trial

What is RenovaCare Forward PE Ratio?

RenovaCare's Forward PE Ratio for today is 0.00.

RenovaCare's PE Ratio without NRI for today is 0.00.

RenovaCare's PE Ratio for today is 0.00.


RenovaCare Forward PE Ratio Historical Data

The historical data trend for RenovaCare's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RenovaCare Forward PE Ratio Chart

RenovaCare Annual Data
Trend
Forward PE Ratio

RenovaCare Quarterly Data
Forward PE Ratio

Competitive Comparison of RenovaCare's Forward PE Ratio

For the Biotechnology subindustry, RenovaCare's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RenovaCare's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RenovaCare's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where RenovaCare's Forward PE Ratio falls into.



RenovaCare Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


RenovaCare  (OTCPK:RCAR) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


RenovaCare Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of RenovaCare's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


RenovaCare (RenovaCare) Business Description

Traded in Other Exchanges
N/A
Address
9375 East Shea Boulvard, Suite 107-A, Scottsdale, AZ, USA, 85260
RenovaCare Inc is a biotechnology company focusing on the acquisition, research, development and commercialization of autologous cellular therapies that can be used for medical and aesthetic applications. The company's initial products under development target skin. It offers treatment methodology for cell isolation for the regeneration of human skin cells, along with a medical-grade liquid spraying device and associated equipment (the SkinGun). RenovaCare is evaluating the efficacy and potential of SkinGun, in combination with a cell isolation method, in the treatment of tissue that has been subject to severe trauma. Geographically all the activities are functioned through the region of United States.
Executives
Patsy Trisler officer: Vice President 430 PARK AVENUE, SUITE 702, NEW YORK NY 10022
Thomas Bold officer: President & CEO 430 PARK AVENUE, SUITE 702, NEW YORK NY 10022
Joseph Sierchio director 430 PARK AVENUE, SUITE 702, NEW YORK NY 10022
Kenneth Kirkland director 430 PARK AVENUE, SUITE 702, NEW YORK NY 10022
Rhonda Beth Rosen director, officer: President & CEO 43 DICKINSON ROAD, BASKING RIDGE NJ 07920
1420525 Alberta Ltd. 10 percent owner 1628 WEST 1ST AVENUE, SUITE 216, VANCOUVER A1 V6J1G1
David E Jenkins director 406 NORTH HERMOSA DRIVE, PALM SPRINGS CA 92262
Antonino G Cacace director, officer: President CRUD-Y-GWYNT, CASWELL BAY, SWANSEA X0 SA3 3BU
Jeet Sidhu director 5667 SUNRISE CRESCENT WEST, SURREY, BC A1 V3S 7M4
Derek Cooper officer: President/ CEO
Frank J Fabio officer: CFO/Sec.(Resigned 1/9/2009) 670 BROADWAY, MASSAPEQUA NY 11758
Christian F Hudson director 33 CHURCHILL ROAD, TENAFLY NJ 07670
Harmel S Rayat director, 10 percent owner 700 - 688 WEST HASTINGS STREET, VANCOUVER A1 V6B 1P1
Stanley Wong officer: President/CEO
Terri Dumoulin director, officer: Secretary/Treasurer

RenovaCare (RenovaCare) Headlines

From GuruFocus

RenovaCare Provides Clinical and Corporate Update

By GuruFocusNews GuruFocusNews 03-09-2022